Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Med Klin Intensivmed Notfmed ; 117(3): 209-217, 2022 Apr.
Article in German | MEDLINE | ID: covidwho-1070809

ABSTRACT

BACKGROUND: Hospitalization rates (HR), emergency care prevalence (ECP) and case fatality proportions (CFP) of hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients in one municipality have not been studied, including how these differ from other pandemic or seasonal viral diseases, such as influenza A/B or norovirus. These analyses and their comparison with negative-tested hospitalized patients are the purpose of the present study. METHODS: A total of 67,000 cases of hospitalized patients of a tertiary care hospital and data of the regional health institute were analyzed to calculate HR, ECP and CFP of SARS-CoV­2, influenza A/B and norovirus genotype 1/2. RESULTS: In the city and district of Fürth (Germany), 824 persons (0.34%) tested SARS-CoV-2-positive through 7 May 2020, 162 of whom (19.7%) were hospitalized. Furthermore, 48 out of 91 patients died in hospital (CFP 11.0%). During the flu/norovirus season 2019/2020 992 inhabitants were flu-positive and 135 norovirus-positive, of whom 202 (20.3%) and 125 (91.9%), respectively, were hospitalized. The ECPs were 4.1%, 2.0% and 0.6%. The CFPs of the SARS-CoV-2-, influenza- and norovirus-positive hospital cohort were 29.1%, 3.0% and 1.6%, while CFPs of the negative-tested were 5.9%, 4.8% and 6.9% with an in-hospital mortality of 2.1% for 2020. CONCLUSIONS: While HRs of SARS-CoV­2 and influenza were similar, CFPs differ significantly. CFPs of negative-tested patients were comparable between the three infectious diseases.


Subject(s)
COVID-19 , Caliciviridae Infections , Influenza, Human , COVID-19/epidemiology , Caliciviridae Infections/diagnosis , Caliciviridae Infections/epidemiology , Humans , Influenza, Human/epidemiology , Pandemics , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL